Patient Population

Inclusion:
- Stage 4 or 5 CKD patients undergoing HD with planned primary de novo AVF

Exclusion:
- non primary AVF creation or revision.
- medical indication for anti-platelet agents or known intolerance of agents.

Stratification
- upper vs. lower arm site
- study centre

RANDOMISATION

ARM A
Aspirin & Omega-3 fatty acids

ARM B
Aspirin placebo and Omega-3 fatty acids

ARM C
Aspirin and Omega-3 fatty acids placebo

ARM D
Aspirin placebo & Omega-3 fatty acids placebo

Endpoints
Primary Endpoint: - patency of AVF at 84 days post creation
Secondary Endpoints: - functional patency of AVF at 6 & 12 months post creation
- primary patency time
- secondary patency time